Navigation Links
Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
Date:6/4/2008

ys, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include, without limitation, statements concerning Arno's business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, plans to initiate clinical trials of Arno's product candidates, the success of Arno's product development, or otherwise as to future events. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Examples of the risks and uncertainties include, but are not limited to: the risk that we may not successfully develop and market our products, and even if we do, we may not become profitable; risks relating to the progress of our research and development; risks relating to the rigorous regulatory approval process required for any products that we may develop independently, with our development partners or in connection with our collaboration arrangements; the risk that changes in the national or international political and regulatory environment may make it more difficult to gain U.S. Food and Drug Administration, or FDA, or other regulatory approval of our drug product candidates; risks that the FDA or other regulatory authorities may not accept any applications we file; risks that the FDA or other regulatory authorities may withhold or delay consideration of any applications that we file or limit such applications to particular indications or apply other label limitations; risks that, after acceptance and review of applications that we file, the FDA or other regulatory authorities will not approve the marketing and sale of our drug product candidates; risks relating to our own drug manufacturing operations and the drug manufacturing operations of our third-party suppliers and contract manufacturer
'/>"/>
SOURCE Arno Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
2. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
3. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
4. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
5. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
6. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
9. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
10. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
11. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... Oct. 16, 2014 Eight finalists, all representing ... to present their proposals for a chance to compete ... Sheikh Zayed Institute Second Annual Pediatric Surgical Innovation ... on Friday, Oct. 24, 2014. Selected ... across the US and internationally, the finalists are: ...
(Date:10/16/2014)... , Oct. 16, 2014   NuVascular ... process to create new medical devices that help ... Inc., the company uses cutting-edge nanotechnology that would ... kidney diseases.  The platform technology ... result of $6.6 million in funding obtained from ...
(Date:10/16/2014)... -- Ninety percent of children and adults with acute ... failed to respond to standard therapies went into remission ... at the Perelman School of Medicine at the University ... New England Journal of Medicine . ... presented at the American Society of Hematology,s annual meeting ...
Breaking Medicine Technology:Finalists for Children's National Health System pediatric medical device competition announced 2Finalists for Children's National Health System pediatric medical device competition announced 3Finalists for Children's National Health System pediatric medical device competition announced 4Nanotechnology Venture Targets Arterial, Heart and Kidney Diseases 2Nanotechnology Venture Targets Arterial, Heart and Kidney Diseases 3Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 2Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 3Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 4Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 5Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 6
... (NASDAQ – YDNT) today announced that its Board of Directors ... December 15, 2011 to all shareholders of record on November ... dividend of $0.04 per share which was also declared on ... commented, "Given the Company,s solid operating performance and strong balance ...
... AMGN ) today announced that it will report ... after the close of the U.S. financial markets. The announcement ... community at 2:00 p.m. Pacific Time.  Participating in the call ... officer, and other members of Amgen,s senior management team. ...
Cached Medicine Technology:Young Innovations, Inc. Board of Directors Declares Special Cash Dividend 2Amgen Announces Webcast of 2011 Third Quarter Financial Results 2
(Date:10/19/2014)... Dallas, Texas (PRWEB) October 20, 2014 ... therapeutic development for Partial Seizure, complete with comparative ... target, mechanism of action (MoA), route of administration ... and featured news and press releases. It also ... for Partial Seizure and special features on late-stage ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides ... its latest designs of 2014 mother of the ... outfits are offered with big discounts, up to 70% ... 30 can enjoy this special offer. , Owing ... has become one of the leading brands in the ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Stephen T. Greenberg, ... been nominated for the 10th consecutive year as one of ... Dr. Greenberg was also been nominated as the best provider ... also nominated as best Day Spa and best Laser Treatment ... December 14th and readers can vote for the contest once ...
(Date:10/19/2014)... OCTOBER 20, 2014 – The U.S. Government has ... treat Alzheimer,s disease by 2025. However, a workgroup ... the research milestones in the U.S. Government,s National ... in scope, increased in scale, and adequately funded ... series of proposals by the workgroup to enlarge ...
(Date:10/19/2014)... Dallas, Texas (PRWEB) October 19, 2014 ... in demand for proton therapy despite the high-cost structure ... resulting in market growth. , Analysts forecast the Global ... CAGR of 9.50 percent over the period 2013-2018. According ... this market is the technological advances in medical diagnostics ...
Breaking Medicine News(10 mins):Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Dr. Stephen T. Greenberg – Nominated for the 10th Consecutive Year for One of Long Island’s Best Cosmetic Surgeons for 2015 by the Long Island Press 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 3Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 4Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 5Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 6Health News:Proton Therapy Market to Grow at 9.50% CAGR to 2018 Forecasts a New Research Report at Sandlerresearch.org 2Health News:Proton Therapy Market to Grow at 9.50% CAGR to 2018 Forecasts a New Research Report at Sandlerresearch.org 3Health News:Proton Therapy Market to Grow at 9.50% CAGR to 2018 Forecasts a New Research Report at Sandlerresearch.org 4
... Offers a Simple Guide to Organizing Matters of Life ... are not organized with,medical information and life documents to ... Yorong in Lifetime Medical Organizer: A Simple,Guide to Organizing ... (published by AuthorHouse), the new book she wrote with,Richard ...
... Eight Alternatives to Exercise-Induced Asthma, INDIANAPOLIS, May ... chest pains while engaged in physical,activity, the default ... from,exercise-induced asthma (EIA). However, there are several other,explanations ... left untreated. A featured science session at the ...
... 10-K Extension ... ... KVa/KVb), a fully integrated specialty pharmaceutical company that,develops, manufactures, acquires and ... to complete and file its fiscal 2008 Form,10-K with the Securities ...
... Water Beverage Presents Exercise Hydration Without the ... ... A new study presented at the,American College of Sports Medicine Annual ... beverage,developed by researchers for Scientific Food Solutions, LLC, for active,persons hydrates ...
... Paul Sierzenski, MD, RDMS, of Christiana Care Health System, ... care workers with immediate access to patient medical records ... that using radiofrequency devices that electronically contain a persons ... aid and reduce medical charges, two often incompatible goals. ...
... a new study, knowledge of potentially toxic household substances ... The results show that less than one-third of primary ... correctly estimate the toxicity of household poisons. The study ... Medicines 2008 Annual Meeting. , Led by Rika N. ...
Cached Medicine News:Health News:Lifetime Medical Organizer 2Health News:Pediatric Wheezing: If Not Asthma, Then What is It? 2Health News:Pediatric Wheezing: If Not Asthma, Then What is It? 3Health News:KV Pharmaceutical Company Updates Timing of Fiscal 2008 Securities and Exchange Commission Filings 2Health News:KV Pharmaceutical Company Updates Timing of Fiscal 2008 Securities and Exchange Commission Filings 3Health News:Zero-Calorie Aqua-Lyte(R) Hydrates as Well as Traditional Sports Drinks 2Health News:Zero-Calorie Aqua-Lyte(R) Hydrates as Well as Traditional Sports Drinks 3
... The total ergonomic solution and best ... Soft, feather touch action and ultra lightweight ... Stress-free tip ejection with long, lever tip ... identification , Accepts universal tips or for ...
... The Finnpipette BioControl ... innovative features as the ... universal handle fits allseven ... channel tip cone modules. ...
... The Research pro Electronic Pipette is ... the laboratory. Its easy-to-follow display, ergonomically-placed operating ... pipetting, dispensing, reverse pipetting and diluting make ... the simple functions of a manual pipette ...
... Design for Unparalleled Comfort Pick one of ... balance. Notice the trigger and ejector positionsright where ... our pipettors are ergonomically designed to help avoid ... pipetting. Productivity In The Palm Of Your ...
Medicine Products: